Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.

Published in: Journal of medical economics (2023)

TARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators.

Keyphrases